MedTrace Logo

Targeting of Immune Response After Pneumococcal Vaccination

NCT01402245 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2011-07-26

No results posted yet for this study

Summary

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Conditions

  • Pneumococcal Pneumonia

Interventions

BIOLOGICAL

Pneumococcal polysaccharide vaccine

Pneumococcal polysaccharide vaccine 0.5 ml i.m.

BIOLOGICAL

pneumococcal conjugate vaccine

pneumococcal conjugate vaccine 0.5 ml i.m.

Sponsors & Collaborators

  • Helsinki University Central Hospital

    lead OTHER

Principal Investigators

  • Anu Kantele, MD PhD · Helsinki University Central Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01402245 on ClinicalTrials.gov